KIORA PHARMACEUTICALS INC (KPRX): Nasdaq/NYSE listing notice — Kiora receives Nasdaq deficiency notice for stock below $1.00

KIORA PHARMACEUTICALS INC

Bid price closed below $1.00 for 30 consecutive business days as of July 18, 2023.
Company has 180 calendar days, until January 15, 2024, to regain compliance.
To cure, closing bid price must be at least $1.00 for 10 consecutive trading days.
If not cured, Kiora may be eligible for a second 180-day period if other listing standards are met.
Company is evaluating options but cannot assure compliance or continued listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

KIORA PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

July 18, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s common

View on SEC.gov

Browse all listing & compliance notices →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-23-000107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.